NewsMarkets

Business

Novartis Abandons Heart Drug After Study Failure

The pharmaceutical company is largely abandoning the experimental treatment after a key study found it had little promise for preventing heart attacks and cardiovascular deaths.

2 publishers · 2 articles · first seen 7 Nov 2026 · updated 8d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

2 publishers have covered this in 2 articles since 7 Nov 2026. Bloomberg.com published first, on 7 November at 14:50 UTC. The most recent article, from STAT, appeared on 7 November at 14:50 UTC.

Outlets reporting it: Bloomberg.com (major outlet), STAT.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Novartis Abandons Heart Drug After Surprising Failure in Key Study Bloomberg.com ·
  2. STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy STAT

In this story

  • Novartis
Embed this story

Paste this into any web page to show the live odds, with a link back here.